Evidence map›Paper›PMID 35309321›Full record

ArticleFrontiers in immunology2022

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuichiro IwamotoDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Takatoshi AnnoDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Katsumasa KoyamaDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Fumiko KawasakiDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Kohei KakuDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Koichi TomodaDepartment of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
Seiko SugiyamaDepartment of Dermatology, Kawasaki Medical School, Okayama, Japan.
Yumi AoyamaDepartment of Dermatology, Kawasaki Medical School, Okayama, Japan.
Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can cause BP, although precise mechanism of DPP-4i-related BP remains unclear. In this report, we showed a case with appearance of various disease-specific antibodies after the onset of DPP-4i-related BP. Furthermore, various disease-specific antibodies became positive and showed high titers two years after the onset of DPP-4i-related BP and discontinuation of DPP-4i. These data showed that it is possible for immune tolerance to be broken after the onset of DPP-4i-related BP, and it may be important to check autoimmune antibodies in DPP-4i-related BP subjects even when BP symptoms are improved.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsPemphigoid, BullousDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHypoglycemic Agentsautoantibodiesbullous pemphigoiddipeptidyl peptidase-4 inhibitordipeptidyl peptidase-4 inhibitor-associated bullous pemphigoidtype 2 diabetes mellitus

Identifiers

PMID35309321
PMCPMC8927025

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.